Trontinemab Fuels Hope for Brain Shuttle Lift-Off
The transferrin receptor-targeted, anti-Aβ antibody swiftly cleared amyloid throughout the brain. It caused little ARIA, though lots of infusion reactions.
The transferrin receptor-targeted, anti-Aβ antibody swiftly cleared amyloid throughout the brain. It caused little ARIA, though lots of infusion reactions.
Tau fragments, alone or with other proteins, can help identify people with high tangle burden. This could help select people for trials or therapy.
Real-world data hints that plasma markers can pick up Alzheimer’s pathology before people have memory complaints.
Fully automated test may be as accurate as mass spec, and more scalable
The spatial extent of tau pathology better correlates with disease severity, and stages disease more accurately, than does tangle load.
Decreased lysosomal efficiency could result from shifts in endosomal recycling.
DIAN-TU explains how it selects APP, PSEN1, and PSEN2 genetic variants for clinical trial inclusion.
After one TREM2 agonist antibody nose-planted, a new batch of therapies appear safe so far in first-in-human data. The drugs exert different effects on the receptor and soluble TREM2.
Our next batch of news reports from the 30th AD/PD conference in Vienna brings you a twisting tale of findings about the important microglial receptor TREM2, as well as a story about efforts to track tau’s spread through the Alzheimer’s brain as a way to measure drug effect. Stay tuned this week for more news about how tau-based plasma tests are diversifying as they approach staging, real-world study, and FDA approval. Meanwhile, DIAN and Alzforum have added trial-eligibility information to APP and PS1/PS2 pathogenic mutations.
New in last 7 days
Latest Comments